Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 10/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | RAC1 | P63000 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6459229 | 1.00 | NPC1 (0.62) | NPC1RAB9AADRA2AMCHR1MAPT | |
| SCHEMBL13793198 | 0.86 | MCHR1 (0.73) | NPC1RAB9AADRA2AMCHR1MAPT | |
| SCHEMBL6458601 | 0.85 | MCHR1 (0.71) | ADRA2AMCHR1KMT2A | |
| SCHEMBL6462789 | 0.85 | MCHR1 (0.71) | ADRA2AMCHR1KMT2A | |
| Hydrochloric Acid SCHEMBL6459622 | 0.85 | MCHR1 (0.70) | ADRA2AMCHR1KMT2A | |
| Hydrochloric Acid SCHEMBL6459631 | 0.85 | MCHR1 (0.70) | ADRA2AMCHR1KMT2A | |
| SCHEMBL6457673 | 0.84 | MITF (0.48) | ADRA2AMCHR1GAAL3MBTL1KDM4E | |
| SCHEMBL6462071 | 0.84 | MITF (0.48) | ADRA2AMCHR1GAAL3MBTL1KDM4E | |
| SCHEMBL6457772 | 0.82 | NPC1 (0.47) | NPC1RAB9AADRA2AMCHR1MAPT | |
| SCHEMBL6457767 | 0.82 | NPC1 (0.47) | NPC1RAB9AADRA2AMCHR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | claimed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | claimed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | NPC1 778/4885RAB9A 1648/4885ADRA2A 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.